Abstract:68Ga-radiolabeled small molecules targeting prostate-specific membrane antigen (PSMA) have been extensively investigated as 68Ga-positron emission tomography (68Ga-PET) tracers. Nevertheless, current 68Ga-labeled radiotracers suffer from either fair detection rates for metastatic prostate cancer lesions or a high uptake by the kidneys. This study synthesizes new PSMA-targeted radiotracers, [68Ga]SC691-DOTA, [68Ga]SC691-NOTA, and [68Ga]SC691-HBEDCC, and explores the in vitro and in vivo properties. These three radiotracers enabled PSMA-positive LNCaP tumors to be visualized by micro-PET/CT as early as 5 min post-injection. Biodistribution studies revealed that all three compounds could accumulate in the tumor with high affinity. The kidney’s uptake of [68Ga]SC691-DOTA and [68Ga]SC691-NOTA was comparable but lower than [68Ga]SC691-HBEDCC. [68Ga]SC691-HBEDCC demonstrated the most increased uptake and retention in the tumor over 2 h post-injection and a lower tumor-to-tissue ratio than [68Ga]SC691-DOTA, and [68Ga]SC691-NOTA.

In Vitro and in Vivo Comparative Study of 68Ga-Labeled DOTA-, NOTA-, and HBEDCC-chelated Radiotracers Targeting Prostate-Specific Membrane Antigen